Evidence-led peptide reference
Semax research guide
Updated 10 October 2026 · Editorial standards
An ACTH-derived synthetic peptide investigated in neurological and stress-response research.
Identity and context
What is Semax?
Semax is a synthetic heptapeptide based on the ACTH(4-7) sequence with a Pro-Gly-Pro extension. It was designed to retain selected neurological research properties without the full hormonal activity of adrenocorticotropic hormone.
Its literature is concentrated in particular countries and research groups. That does not invalidate the work, but it makes independent replication, translation quality and direct comparison with UK-authorised treatments especially important.
Mechanism under investigation
How is Semax studied?
Research examines neurotrophic signalling, including expression related to brain-derived neurotrophic factor, as well as inflammatory, oxidative and gene-expression responses after neurological stress. Proposed effects vary by tissue, timing and model.
Descriptions such as “nootropic” or “focus peptide” compress a complex and uncertain evidence base into a consumer promise. Cognitive performance in healthy people has not been established to the standard implied by such labels.
Research map
Main areas of interest
Neurological injury
Experimental and limited clinical work has explored ischaemia, recovery signalling and neurological outcomes.
Neurotrophic pathways
Cell and animal studies examine BDNF-related and other gene-expression changes.
Cognition and stress
Attention, memory and stress responses appear in the literature, but claims for healthy users remain insufficiently established.
Strength of evidence
What does the evidence actually show?
Evidence is separated by level because a cell experiment, an animal model, a human trial and a regulatory decision answer different questions.
Critical reading
Limitations and unanswered questions
- Results after experimental brain injury cannot be generalised to everyday focus or memory enhancement.
- Intranasal research depends on formulation, absorption and validated delivery.
- Much of the literature needs wider independent replication.
- Long-term safety in unsupervised or non-clinical use is not established.
Analytical context
What a certificate of analysis can—and cannot—tell you
A certificate of analysis is a report about the particular submitted sample and tests named on that report. It can help document identity, measured amount or purity when suitable methods were used. It does not prove that every batch is identical, that a material is sterile or endotoxin-free, that it is clinically effective, or that it is approved for human use.
No product-specific COA is currently linked to this guide. Absence of a displayed report should not be interpreted as analytical verification.
Learn how to read a peptide COA →Questions answered
Semax FAQs
Is Semax a steroid hormone?
No. It is derived from a fragment of ACTH but was designed without the full corticosteroid-stimulating activity of the hormone.
Is Semax a proven nootropic?
No. Mechanistic and limited clinical research does not establish broad cognitive enhancement in healthy people.
Why is BDNF mentioned?
Some experimental studies report changes in BDNF-related expression, a pathway involved in neuronal plasticity. That finding alone does not prove a clinical benefit.
Is Semax approved in the UK?
No.
Primary and authoritative reading
Sources and further reading
Sources are provided so readers can inspect the underlying literature and current official information. Inclusion does not mean every claim in a paper has been independently confirmed.
- Semax PubMed study ↗Indexed neurological research on Semax.
- Semax gene-expression research ↗Open-access preclinical gene-expression study.
- Semax rat ischaemia transcriptome study ↗Original preclinical rat study; this is not a review or a human clinical trial.
Source and wording review: 7 October 2026. Prepared with AI assistance; no independent clinical review is claimed. Read the editorial policy or suggest a correction.